Bloodstream Infections in Patients with Hematologic Diseases: Causative Organisms and Factors Associated with Resistance

Abstract

Background Patients with hematologic diseases are at high risk of bloodstream infections (BSIs). This study aimed to analyze clinical features and distributions of microorganisms in patients with hematologic diseases presenting at a tertiary care university-affiliated hospital in Korea. Materials and Methods We retrospectively reviewed all BSI episodes recorded in patient medical records at two hematologic wards of the Catholic Hematology Hospital from January to December 2020. Our aim was to analyze demographic and clinical characteristics relevant to BSIs. We also described the antimicrobial resistance patterns of the major pathogens identified in this study, and evaluated risk factors for extended-spectrum beta-lactamase (ESBL) production in Enterobacteriaceae isolates and for vancomycin resistance in enterococcal isolates. Results A total of 380 BSI episodes were identified in 334 patients over the course of 1 year (monomicrobial BSI episodes, 86.1%; polymicrobial BSI episodes, 13.9%). Gram-negative bacteria accounted for 242 isolates (54.8%). The most frequently isolated Gram-negative bacteria isolates were Escherichia coli (107 [24.2%]) followed by Klebsiella spp. (72 [16.3%]), Pseudomonas spp. (21 [4.8%]), and Enterobacter spp. (12 [2.7%]). The most commonly identified Gram-positive bacteria were Enterococcus spp. (72 [16.3%]) followed by viridans streptococci (54 [12.2%]), coagulase-negative staphylococci (CoNS) (24 [5.4%]), and Corynebacterium spp. (22 [5.0%]). ESBL-producing Enterobacteriaceae accounted for 25.1% of the total distribution. Among 54 Enterococcus faecium isolates, 100.0% were resistant to ampicillin and 55.6% showed resistance to vancomycin, while 100.0% (n = 12) of Enterococcus faecalis isolates were susceptible to ampicillin and vancomycin, respectively. Use of ciprofloxacin prophylaxis (odds ratio: 5.20; 95% confidence interval: 1.11 - 24.34; P = 0.04) was an independent risk factor for ESBL production in Enterobacteriaceae BSIs. Conclusion Compared with the results of a previous study conducted at the same institution, our findings demonstrated that Gram-negative bacteria remained dominant pathogens in BSIs occurring in patients with hematologic diseases. Our findings also demonstrated a comparatively decreased prevalence of ESBL-producing Enterobacteriaceae in the evaluated BSIs. However, the prevalence of enterococcal BSIs had not decreased, and the proportion of vancomycin-resistant Enterococcus isolates from E. faecium BSIs had increased. In addition, we found that ciprofloxacin p...

Bacterial Bloodstream Infections after Allogeneic Hematopoietic Stem Cell Transplantation: Etiology, Risk Factors and Outcome in a Single-Center Study

“…The benefit of FQ prophylaxis in patients receiving HSCT is not standardized or consistent [ 31 , 32 , 33 ]. The results of a survey of Blood and Marrow Transplant Clinical Trials Network centers evaluating antibacterial antibiotic practices among 41 HSCT centers showed that FQ prophylaxis was used in 75% of the centers [ 34 ].…”

Bacterial Infections and Cancer: Exploring This Association And Its Implications for Cancer Patients

“…Several reports highlight that bacterial infections are prevalent in patients with blood cancers [ 99 , 100 , 101 ], owing mainly to prolonged neutropenia during treatment [ 101 ]. Although patients with solid tumors are also susceptible to bacterial infections, an extensive epidemiological study reported an eightfold higher incidence in patients with hematological cancers than in patients with solid tumors [ 102 ].…”

Core Elements for Implementing Antimicrobial Stewardship Programs in Korean General Hospitals

“…Practical guidelines and clinical pathways for each infectious disease tailored to the characteristics of medical facilities are shared in a multifaceted manner to improve the treatment behavior of the medical facility in accordance with the guidelines and increase the frequency of appropriate initial empirical antimicrobial administration [ 47 48 49 ]. Prescription sets and checklists for best practice alerts can be used to incorporate treatment guidelines or policies into the prescription process [ 50 ].…”